Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06727552 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Barzolvolimab in Patients With Atopic Dermatitis

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of May 2026 to May 6, 2026v13
  2. Primary completion moved earlier from Oct 2026 to May 2026
    • Study completion moved earlier from May 2027 to Dec 2026
    v12
  3. Study sites: 39 to 33v11
  4. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 120 to confirmed 131
    • Start date: Jan 7, 2025 to Dec 18, 2024
    • Site details revised at 39 of 39 sites
    v10
  5. Study sites revised (39)v9
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 24 to 39v8
  2. Study sites: 17 to 24v7
  3. Study sites: 6 to 17v6
  4. Study sites: 1 to 6v5
  5. Start date changed from estimate of Dec 2024 to Jan 7, 2025v4
  6. Eligibility criteria shortened, about 9 words
    • Study title shortened, about 2 words
    v3
  7. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis
Trial Details
NCT Number NCT06727552
Lead Sponsor Celldex Therapeutics
Conditions
(from sponsor)		 Atopic Dermatitis
Related terms Dermatitis, Atopic, Eczema
Enrollment 131 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov